TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27345655

Group type: EXPERIMENTAL
Intervention: Intravesical BCG vaccine or intravesical chemotherapy for non-muscle-invasive bladder cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radical cystectomy with neoadjuvant chemotherapy for muscle-invasive bladder cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bladder-sparing trimodality treatment consisting of transurethral resection with chemoradiation for selected patients with muscle-invasive tumours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic cisplatin-based chemotherapy for advanced disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunotherapy as a salvage treatment for patients in whom first-line chemotherapy cannot control the disease
Number of subjects: 0
Study: 27347089

Group type: EXPERIMENTAL
Intervention: LTD4 nasal provocation test
Number of subjects: 42
Study: 27347377

Group type: EXPERIMENTAL
Intervention: Modified-release lovastatin-lactone (SYN-010)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27347547

Group type: EXPERIMENTAL
Intervention: Mobility Enhancing Nursing Intervention (MFP) combined with standard care for 30 days
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard care (Control Group)
Number of subjects: 140
Study: 27347680

Group type: EXPERIMENTAL
Intervention: Cenicriviroc (CVC) at doses ≥20 mg/kg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cenicriviroc (CVC) in the NASH model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cenicriviroc (CVC)
Number of subjects: 0
Study: 27349654

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) intervention using Samsung Gear VR goggles
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) intervention
Number of subjects: 30
Study: 27349898

Group type: EXPERIMENTAL
Intervention: SmokefreeText (SFTXT) program
Number of subjects: 4027

Group type: EXPERIMENTAL
Intervention: Text message delivery variations
Number of subjects: 4027
Study: 27350064

Group type: EXPERIMENTAL
Intervention: LY2603618 (150 mg/m², day 2) and pemetrexed (500 mg/m², day 1) every 21 days until disease progression
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: LY2603618 and pemetrexed combination therapy
Number of subjects: 55
Study: 27350760

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg with clopidogrel 600 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Clopidogrel 600 mg alone
Number of subjects: 60
Study: 27351006

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/d for 6 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 27351341

Group type: EXPERIMENTAL
Intervention: Ledipasvir (90 mg) plus Sofosbuvir (400 mg) once daily for 12 weeks
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Ledipasvir plus Sofosbuvir
Number of subjects: 44
Study: 27352238

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 150mg once daily (qd)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 150mg qd
Number of subjects: 112
Study: 27352735

Group type: EXPERIMENTAL
Intervention: Mifepristone 200mg followed by misoprostol 600μg sublingual 24-48 hours later
Number of subjects: 290

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 290
Study: 27352953

Group type: EXPERIMENTAL
Intervention: Cardiovascular autonomic neuropathy (CAN) measures
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Valsalva ratio ≤1.5
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: R-R variation increase
Number of subjects: 580
Study: 27352954

Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Number of subjects: 0
Study: 27353267

Group type: EXPERIMENTAL
Intervention: TDF/FTC therapy for at least 30 days
Number of subjects: 40
Study: 27353816

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 27353819

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 27354021

Group type: EXPERIMENTAL
Intervention: CD25/regulatory T-cell-depleted donor lymphocyte infusion
Number of subjects: 0
Study: 27354044

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 6020

Group type: COMPARATOR
Intervention: North America (NA)
Number of subjects: 6020

Group type: COMPARATOR
Intervention: Western Europe (WE)
Number of subjects: 6020

Group type: COMPARATOR
Intervention: Central/Eastern Europe/Russia (CEER)
Number of subjects: 6020

Group type: COMPARATOR
Intervention: Latin America (LA)
Number of subjects: 6020

Group type: COMPARATOR
Intervention: Asia-Pacific (AP)
Number of subjects: 6020

Group type: COMPARATOR
Intervention: Latin America (LA) and Asia-Pacific (AP)
Number of subjects: 6020
Study: 27354104

Group type: EXPERIMENTAL
Intervention: Endorectal US (ERUS) measurements before (ERUS1), during (ERUS2), and after (ERUS3) CRT
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Endorectal US (ERUS) measurements after CRT (ERUS3)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Cut-off values for ERUS3
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Good prognosis group based on ERUS3 values
Number of subjects: 41
Study: 27354274

Group type: EXPERIMENTAL
Intervention: Increasing deprivation quartiles in women
Number of subjects: 8916

Group type: EXPERIMENTAL
Intervention: Increasing deprivation quartiles in men
Number of subjects: 8916

Group type: EXPERIMENTAL
Intervention: Most deprived women
Number of subjects: 8916

Group type: EXPERIMENTAL
Intervention: Third quartile of deprivation in men
Number of subjects: 8916
Study: 27354423

Group type: EXPERIMENTAL
Intervention: Remote zone ECV measurement at 2 days post STEMI
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Multivariable regression analysis
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Change in remote zone ECV (ΔECV)
Number of subjects: 271
Study: 27354476

Group type: EXPERIMENTAL
Intervention: Pembrolizumab, 10 mg/kg every 2 weeks until disease progression
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 31
Study: 27354477

Group type: EXPERIMENTAL
Intervention: Osimertinib (AZD9291)
Number of subjects: 58
Study: 27354481

Group type: EXPERIMENTAL
Intervention: Nivolumab 10 mg/kg plus gemcitabine-cisplatin
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Nivolumab 10 mg/kg plus pemetrexed-cisplatin
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Nivolumab 10 mg/kg plus paclitaxel-carboplatin
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Nivolumab 5 mg/kg plus paclitaxel-carboplatin
Number of subjects: 56
Study: 27354485

Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg intravenously every 2 weeks until progression or unacceptable toxicity
Number of subjects: 52
Study: 27354719

Group type: EXPERIMENTAL
Intervention: Lenalidomide-bendamustine-rituximab (L-B-R)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rituximab-bendamustine (R-B)
Number of subjects: 0
Study: 27355323

Group type: EXPERIMENTAL
Intervention: Treatment with Pegylated-interferon
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Higher social function (<10 vs ≥15)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Treatment (HCV n = 74, SVR 55%; HCV/HIV n = 37, SVR 74%)
Number of subjects: 163
Study: 27355505

Group type: EXPERIMENTAL
Intervention: HOPE (home-based education and HIV testing)
Number of subjects: 601

Group type: COMPARATOR
Intervention: INVITE (written invitations for male partners to attend clinic)
Number of subjects: 601
Study: 27355533

Group type: EXPERIMENTAL
Intervention: Midostaurin (100 mg twice daily)
Number of subjects: 116
Study: 27355620

Group type: EXPERIMENTAL
Intervention: Real-time PCR assay targeting the 529 bp repeat region of T. gondii in blood samples
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Real-time PCR assay in blood samples
Number of subjects: 44
Study: 27355865

Group type: EXPERIMENTAL
Intervention: MMP-9 concentrations in cerebrospinal fluid (CSF) within 24 hours after admission.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CSF MMP-9 concentrations at 24 hours.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: MMP-9 concentrations in plasma and CSF measured within 48 hours after subarachnoid haemorrhage.
Number of subjects: 30
Study: 27356482

Group type: EXPERIMENTAL
Intervention: Chronic l-citrulline supplementation
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no l-citrulline supplementation)
Number of subjects: 23
Study: 27356502

Group type: EXPERIMENTAL
Intervention: Antenatal care attendance (average of four visits)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Community-based initiatives
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Government programs and increased availability of maternity services
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Postpartum care
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Factors influencing care-seeking
Number of subjects: 35
Study: 27356754

Group type: EXPERIMENTAL
Intervention: Traditional medicine provided by traditional birth attendants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Economic factors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Innovative mechanisms for health care financing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Engagement of stakeholders including policy makers and health care providers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Addressing socio-cultural factors such as patriarchy
Number of subjects: 0
Study: 27356863

Group type: EXPERIMENTAL
Intervention: Health care utilization influenced by social, economic, and cultural factors; decision-making by husbands and mothers-in-law.
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Preference for private facilities due to perceived superior quality of services.
Number of subjects: 173
Study: 27356968

Group type: EXPERIMENTAL
Intervention: Antenatal care sought at health facilities
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional healers and community health workers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community saving schemes for transport and medication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Involvement of key family members in pregnancy follow-up
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prompt referrals to health facilities by community-based health care providers
Number of subjects: 0
Study: 27357090

Group type: EXPERIMENTAL
Intervention: Tanaka equation
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: INTERSALT equation
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Nerbass equation
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 129
Study: 27357108

Group type: EXPERIMENTAL
Intervention: Surgically treated colorectal cancers and resected colorectal liver metastases
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Blood samples and fresh-frozen tumour and normal tissue for investigation of circulating tumour cells (CTCs) and novel biomarkers
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tumour specimens investigated by immunohistochemistry
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Molecular classes beyond the TNM staging
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Hot spot panels for known mutations in CRC
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Immune-cell characteristics
Number of subjects: 120
Study: 27357194

Group type: EXPERIMENTAL
Intervention: Standardised interviews with patients
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Standardised interviews with GPs
Number of subjects: 1200
Study: 27357198

Group type: EXPERIMENTAL
Intervention: 12-week exercise programme consisting of group-based supervised training two times a week, including progressive resistance training and aerobic training.
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: 12-week exercise programme
Number of subjects: 169
Study: 27357358

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-cTnT) introduction
Number of subjects: 2544
Study: 27357359

Group type: EXPERIMENTAL
Intervention: Anticoagulation therapy (specifics not provided)
Number of subjects: 17162

Group type: EXPERIMENTAL
Intervention: Comprehensive management approach including anticoagulation and targeting modifiable risk factors
Number of subjects: 17162
Study: 27357468

Group type: EXPERIMENTAL
Intervention: Circulating histones
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Peak histone levels
Number of subjects: 48
Study: 27357579

Group type: EXPERIMENTAL
Intervention: Community health worker interventions for identification and emergency management of pre-eclampsia and eclampsia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative and quantitative methods for feasibility assessments
Number of subjects: 0
Study: 27357695

Group type: EXPERIMENTAL
Intervention: Cultural perceptions of pre-eclampsia and eclampsia; no specific intervention reported
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Traditional treatments for seizures; herbs, concoctions, incisions, topical application of black soap
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Public health awareness initiatives
Number of subjects: 323
Study: 27357738

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (1.71 mg/kg for 3 days, then 2.14 mg/kg if no safety concerns)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Number of subjects: 9
Study: 27357835

Group type: EXPERIMENTAL
Intervention: Patient portal use
Number of subjects: 9133
Study: 27357840

Group type: EXPERIMENTAL
Intervention: Community understanding of pre-eclampsia and eclampsia
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Local beliefs regarding causes of hypertension in pregnancy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Local beliefs regarding seizures in pregnancy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Warning signs for pre-eclampsia and eclampsia
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Community education regarding pregnancy complications
Number of subjects: 30
Study: 27358068

Group type: EXPERIMENTAL
Intervention: Community perceptions of pre-eclampsia and eclampsia
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Community knowledge and attitudes towards hypertension in pregnancy
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Home remedies for seizures
Number of subjects: 219
Study: 27358078

Group type: EXPERIMENTAL
Intervention: EvidenceNOW Initiative interventions including practice facilitation, expert consultation, performance feedback, and educational materials and activities.
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: EvidenceNOW Initiative interventions
Number of subjects: 1500
Study: 27358088

Group type: EXPERIMENTAL
Intervention: Non-invasive 24-hour ambulatory blood pressure monitoring (ABPM) and arterial stiffness estimates (through 24-hour pulse wave analysis, PWA)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: 24-hour pulse wave analysis (PWA)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: 24-hour PWA
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Arterial stiffness, BP absolute mean level and variability
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: 24-hour PWA electronic health (e-health) solution
Number of subjects: 2000
Study: 27358422

Group type: EXPERIMENTAL
Intervention: Increased dietary variety (T3)
Number of subjects: 367
Study: 27358490

Group type: EXPERIMENTAL
Intervention: Low-dose group (LdD, received 1,000 IU VitD daily)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: High-dose group (HdD, received 5,000 IU VitD daily)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (CG, did not receive VitD)
Number of subjects: 150
Study: 27358494

Group type: EXPERIMENTAL
Intervention: 1 week of strict bed rest
Number of subjects: 10
Study: 27362300

Group type: EXPERIMENTAL
Intervention: Robatumumab (19D12; MK-7454; SCH717454) administered every 2 weeks
Number of subjects: 144
Study: 27362533

Group type: COMPARATOR
Intervention: Rituximab intravenous (IV) infusion
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Rituximab subcutaneous (SC) injection
Number of subjects: 30
Study: 27362845

Group type: EXPERIMENTAL
Intervention: 0.5mg/kg ketamine
Number of subjects: 13
Study: 27363516

Group type: EXPERIMENTAL
Intervention: [2-(14)C](-)-epicatechin (300 μCi, 60 mg)
Number of subjects: 8
Study: 27363577

Group type: EXPERIMENTAL
Intervention: In vivo reflectance confocal microscopy (RCM)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Punch biopsy (usual care)
Number of subjects: 329

Group type: COMPARATOR
Intervention: RCM and punch biopsy
Number of subjects: 329
Study: 27365150

Group type: EXPERIMENTAL
Intervention: Dog ownership
Number of subjects: 123560

Group type: EXPERIMENTAL
Intervention: Cat ownership
Number of subjects: 123560

Group type: EXPERIMENTAL
Intervention: Bird ownership
Number of subjects: 123560

Group type: COMPARATOR
Intervention: Non-pet ownership
Number of subjects: 123560

Group type: EXPERIMENTAL
Intervention: Site-specific cancers
Number of subjects: 123560
Study: 27365540

Group type: EXPERIMENTAL
Intervention: Endometrial Receptivity Array (ERA)
Number of subjects: 0
Study: 27367154

Group type: EXPERIMENTAL
Intervention: Vorinostat 400 mg po qd for 28 days followed by a 7-day treatment-free period (5-week cycle)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vorinostat
Number of subjects: 40
Study: 27367781

Group type: EXPERIMENTAL
Intervention: Intergenic single-nucleotide polymorphism (rs4445257) on chromosome 8
Number of subjects: 581

Group type: COMPARATOR
Intervention: Control group (all other pattern groups)
Number of subjects: 581
Study: 27367949

Group type: EXPERIMENTAL
Intervention: RLS device (targeted pressure on abductor hallucis and flexor hallucis brevis muscles)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: RLS device
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ropinirole vs placebo (historical comparison)
Number of subjects: 30
Study: 27369069

Group type: EXPERIMENTAL
Intervention: Threat condition (unpredictable electrical shock)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Safe condition (no shock)
Number of subjects: 0
Study: 27369488

Group type: EXPERIMENTAL
Intervention: Web-based personalized diet-modification and weight-modification program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard informational health website
Number of subjects: 0
Study: 27369694

Group type: EXPERIMENTAL
Intervention: Jødal and Brøchner-Mortensen (JBM) formula from 2009 with sampling at 2 and 5 hours
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Brøchner-Mortensen method from 1972 with early BSA normalization
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Other formulas with early BSA normalization
Number of subjects: 96
Study: 27369803

Group type: EXPERIMENTAL
Intervention: CoreValve THV with adherence to sizing algorithm
Number of subjects: 1023

Group type: EXPERIMENTAL
Intervention: Higher DARs
Number of subjects: 1023

Group type: EXPERIMENTAL
Intervention: Adherence to sizing algorithm
Number of subjects: 1023
Study: 27370649

Group type: EXPERIMENTAL
Intervention: Targeted fortification of human milk (adding macronutrients to achieve 4.4 g fat, 8.8 g carbohydrates, and 3 g protein per 100 ml)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard fortified human milk
Number of subjects: 10
Study: 27370913

Group type: EXPERIMENTAL
Intervention: Single-dose oritavancin
Number of subjects: 1910

Group type: COMPARATOR
Intervention: Multiple-dose vancomycin
Number of subjects: 1910
Study: 27371698

Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg orally once daily, days 1-21 of a 28-day cycle
Number of subjects: 33
Study: 27373141

Group type: EXPERIMENTAL
Intervention: Liquid formulation of Rotarix™ (GlaxoSmithKline, Belgium)
Number of subjects: 12511

Group type: COMPARATOR
Intervention: Lyophilized formulation of Rotarix™
Number of subjects: 12511
Study: 27373595

Group type: EXPERIMENTAL
Intervention: DTaP-IPV/Hib
Number of subjects: 14042

Group type: COMPARATOR
Intervention: Other DTaP-containing vaccines
Number of subjects: 14042
Study: 27373745

Group type: EXPERIMENTAL
Intervention: Motor Adaptation Cohort (MAC)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Therapeutic Exercise Cohort (TEC)
Number of subjects: 32
Study: 27374464

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg/day plus R-CHOP-21 (intravenous rituximab 375 mg/m(2), intravenous cyclophosphamide 750 mg/m(2), intravenous doxorubicin 50 mg/m(2), intravenous vincristine 1·4 mg/m(2) [maximum 2·0 mg], oral prednisone 100 mg/m(2) on days 1-5 of the cycle) for six cycles.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg/day plus R-CHOP-21
Number of subjects: 24
Study: 27374466

Group type: EXPERIMENTAL
Intervention: Infusion of non-HLA-matched ex-vivo expanded cord blood progenitor cells after chemotherapy
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Infusion of non-HLA-matched ex-vivo expanded cord blood progenitor cells
Number of subjects: 29
Study: 27374829

Group type: EXPERIMENTAL
Intervention: Serum vitamin D (25(OH)D) levels categorized as ≤20 ng/mL
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Predictive model based on supplement intake, nutritional status, race, and estimated creatinine clearance (eCCr)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Nutritional status and adequate supplementation
Number of subjects: 310
Study: 27375040

Group type: EXPERIMENTAL
Intervention: AAV2-hRPE65v2 (1.5 × 10(11) vector genomes) subretinally injected into the contralateral eye
Number of subjects: 11
Study: 27376543

Group type: EXPERIMENTAL
Intervention: Maximal oxygen uptake (VO2 max)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Metabolic flexibility (ΔRQ)
Number of subjects: 136
Study: 27377575

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 774

Group type: COMPARATOR
Intervention: Low-SNOT CRS patients
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: Low-SNOT CRS patients undergoing ESS
Number of subjects: 774
Study: 27377635

Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Number of subjects: 106
Study: 27378554

Group type: EXPERIMENTAL
Intervention: Low platelet reactivity (LTA tertile 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin dose ≥300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass time
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EuroSCORE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tertile distribution of platelet reactivity
Number of subjects: 0
Study: 27378875

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 46